Editor's Note: This column tracks the latest Wall Street ratings and price targets daily to uncover potential investment opportunities.

Market context. In the previous session, U.S. equities edged higher — Dow Jones Industrial Average(DJI.US)+0.98% (53,277.01), S&P 500 index(SPX.US) +0.43% (7,674.37), NASDAQ(IXIC.US) +0.43% (26,180.45); Long-end Treasury yields kept rising (10Y 4.734%, 30Y 5.273%); ING noted the Treasury's attempts to cap yields only highlight the underlying fiscal problem. The week ahead turns to Chair Kevin Warsh's Jackson Hole keynote (Aug 29) and NVIDIA Corporation(NVDA.US)'s Q2 FY27 print (Aug 27 AMC). Sector-wise financials led (Goldman +3%, VISA/AmEx +1%); precious metals and crypto-linked stocks rallied — spot gold +1.89% to $4,604.53/oz (up ~5% in the week after breaking $4,400/$4,450/$4,500/$4,600), Robinhood(HOOD.US) +13.68%, Coinbase(COIN.US) +8%; the Moderna(MRNA.US)- Merck & Co., Inc.(MRK.US) vaccine theme extended; Tesla Motors, Inc.(TSLA.US) +5% on Cybercab momentum.

Five key takeaways from today's ratings actions:

Biotech & pharma see the densest upgrades today. The biotech and pharma sector saw 7 upgrades today (11% of total upgrades). Examples: Ultragenyx Pharmaceutical, Inc.(RARE.US) was raised by Morgan Stanley from $67 to $74; $SLDB was raised by Truist Securities from $16 to $20. These names are high-beta and volatile, mostly single-house views — more a high-beta theme play than a consensus call.

Consumer & Retail: One stock, two opposing views. Alibaba Group Holding Ltd. Sponsored ADR(BABA.US) saw both an upgrade and a downgrade today: J.P. Morgan and Barclays raised its target price, while Baird lowered it. This simultaneous clash between bulls and bears indicates that while the sector is gaining attention, institutions are divided on its short-term valuation.

Autos & Mobility are under pressure today. The sector saw 10 downgrades (Advance Auto Parts, Inc.(AAP.US), etc. — 10 rating actions), contrasting with the main trend and showing that capital is rotating between sectors rather than going all-in on the long side.

Institutional new coverage is active. Today, 25 new initiations landed across multiple sub-sectors; fresh coverage often signals sell-side re-rating and is worth tracking for follow-on actions.

Penny stocks inflate the "upside leaderboard" impression. 4 of the top-10 implied upsides are penny names — the numbers look dramatic, but liquidity is thin, volatility is high, and most reflect single-house views, so their reference value should be discounted.

In short: Biotech & Pharma take center stage today, with Consumer & Retail seeing divergence, and Autos & Mobility facing pressure. With 61 upgrades vs 80 downgrades, sentiment is roughly balanced. The high upside in penny stocks carries noise — don't read the numbers at face value.

📌 Today's Key Ratings Focus: Morgan Stanley upgrades Ultragenyx Pharmaceutical, Inc.(RARE.US) to $74 (Overweight) | Truist Securities upgrades Solid Biosciences Inc.(SLDB.US) to $20 (Buy) | J.P. Morgan upgrades Alibaba Group Holding Ltd. Sponsored ADR(BABA.US) to $210 (Overweight) | Wells Fargo initiates Accel Entertainment, Inc. Class A(ACEL.US) at $14 (Equal-weight) | Lake Street downgrades FLUX POWER HOLDINGS INC(FLUX.US) to $4 (Buy)

🔍 Rating Spotlight: ImageneBio, Inc.(IMA.US)

HC Wainwright initiates ImageneBio, Inc.(IMA.US) at Buy with a $28 target — implying ~+408% upside at the $5.51 price; whether that single-house initiation can be validated by OX40 pipeline data is the core question.

ImageneBio, Inc.(IMA.US) drew an initiation from HC Wainwright today (Buy, $28 target), implying ~408% upside at $5.51. The re-rating thesis rests on Olevaprubart (IMG-007, a non-T-cell-depleting anti-OX40 antibody) Phase 2b atopic dermatitis data and label expansion — the crux of market attention.

The fundamentals come from Q2 2026 results disclosed Aug 5: no product revenue ($0) following the Non-OX40 divestiture, a net loss of $10.18M (-$0.63/share vs -$4.46 a year ago), and $136.2M of cash and marketable securities at Jun 30, funding planned operations into Q1 2028. The company is now single-pipeline — Olevaprubart (IMG-007): the Phase 2b ADAPTIVE trial (moderate-to-severe atopic dermatitis) continues under the amended protocol with topline data expected in Q4 2027, and a long-term extension (LTE) study is enrolling; a Phase 2 alopecia areata trial is planned to initiate in 2026, with initial data expected in 2028.

Today's sample shows only HC Wainwright initiating $IMA (Buy, $28). Sell-side pricing is thin and one-directional: Leerink set a $30 Outperform target in Oct 2025, while Wedbush (Underperform) and Weiss (Sell) remain negative — a $28-$30 target range sitting alongside negative ratings signals an extreme expectation gap. The +408% implied upside comes largely from this single initiation, so its reference value should be discounted.

At $5.51, ImageneBio, Inc.(IMA.US) sits ~40% above its 52-week low of $3.94 but ~62% below the $14.34 high — a stark divergence between a beaten-down share price and lofty sell-side targets. This is not a sector story: as a pre-revenue clinical-stage small-cap biotech, $IMA's tape is driven by its own pipeline events and financing/dilution expectations, not sector beta. Skeptics anchor on three things — the pre-revenue clinical-stage profile, a competitive OX40-signaling field across indications like atopic dermatitis, and the long wait until the Phase 2b topline (Q4 2027) — while sell-side targets express conviction in the differentiated 'non-depleting anti-OX40 plus extended half-life' path.

Key questions for subsequent validation:

(1)Can the ADAPTIVE Phase 2b topline (expected Q4 2027) demonstrate differentiation on primary endpoints, rather than merely matching existing OX40-pathway competitors?
(2)Will the $136.2M cash (into Q1 2028) last until the Phase 2b readout, and will initiating the alopecia areata Phase 2 in 2026 require extra financing and dilution?
(3)With a single pipeline after the Non-OX40 divestiture, does the company lack an alternative value anchor if ADAPTIVE underwhelms?
(4)The +408% implied upside comes largely from one initiation — is this the start of a trend re-rating, or a fleeting event-driven overvaluation?

If ADAPTIVE Phase 2b reads out positively or regulators/partners endorse the differentiation, shares could gravitate toward the sell-side targets ($28-$30). If data disappoints or competition intensifies, the bear case revisits the 52-week low area (~$4) or below. The Phase 2b topline (Q4 2027) and the 2026 alopecia areata Phase 2 initiation are the nearest key windows.

Overall Assessment:

Summary: ImageneBio, Inc.(IMA.US)'s big upside is driven by a single-house initiation. The +408% target price reflects an individual institution's optimistic assumptions rather than market consensus; the key validation for small-cap biotech still depends on upcoming clinical data and regulatory milestones.

📋 Rating Board | Top 10 Upside Potential

Top 10 Upside Potential (Ratings data as of Aug 24)

🔎 Key Observation: Within the Top 10, FLUX POWER HOLDINGS INC(FLUX.US) / Electra Battery Materials Corp(ELBM.US) / MDxHealth S.A.(MDXH.US) / Envoy Medical, Inc. Class A(COCH.US) saw "target price downgrades"—their stock prices plummeted, but analysts' new targets remain far above current prices, so the "upside" was created by the crash. Such "big upside" reflects survivorship bias; fundamentals should determine whether these are oversold gems or value traps (see Contrarian Radar for details).

Today's Rating Actions: Upgrades 61 | Initiations 25 | Downgrades 80 (Data from public rating sources).

🔬 Recent Institutional Insights

Below is a curated roundup of recent Wall Street views on trending US equities. Provided for informational purposes only.

Ross Stores, Inc.(ROST.US)

Ross Stores drew 11 same-day target-price hikes on Aug 24, with the cluster running from $231 up to $310 — Barclays $260→$298, JPMorgan $262→$272, Truist $290→$310 (the highest end), Evercore ISI $276→$290, Citi $270→$290, Jefferies $265→$285, William Blair $250→$270, UBS $232→$239, Morgan Stanley $231→$234, Wells Fargo $245→$248, Bernstein $230→$240, implying 15%-25% upside across the board. An unusually broad consensus upgrade for an off-price retailer, with sell-side increasingly revising up its comp-store and earnings view.

Deere & Company(DE.US)

Deere drew four target hikes on Aug 24 as institutions repriced the agricultural cycle — Citi $610→$650, William Blair $525→$640 (+22%, the largest), Oppenheimer $680→$685, JPMorgan $570→$585 — while UBS nudged down to $728 (still a Buy). The cluster of hikes signals growing belief that U.S. and global farm-equipment demand has bottomed, consistent with USDA crop-price stabilization and farmer-aid expectations. Precision agriculture and automation at Deere is being treated as a long-duration cash-flow pillar alongside the cyclical recovery.

NVIDIA Corporation(NVDA.US)

NVIDIA's biggest event of the week — the Q2 FY27 print after the bell on Aug 27 (confirmed on its Investor Relations page) — will be parsed for data-center Blackwell/Rubin ramp, gross-margin trajectory, and Q3 guidance. On Aug 24, BMO initiated coverage at Outperform with a $340 PT (as part of a cluster also covering AMD $550 / AVGO $455 / ADI $430 / MCHP $95 / MRVL $250 / SWKS $70, etc.), reflecting a broad semi-sector constructive reset. The bull case for NVDA still hinges on AI compute — customer capex conversion, the ASIC/XPU substitution pace, and Hopper/Blackwell inventory dynamics — with implied upside set by management's commentary on Blackwell ramp and forward guidance on the call.

🎯 Contrarian Radar

Signal 1: FLUX POWER HOLDINGS INC(FLUX.US), Electra Battery Materials Corp(ELBM.US), MDxHealth S.A.(MDXH.US), Envoy Medical, Inc. Class A(COCH.US) — "Downgraded but retaining massive implied upside" in penny stocks

FLUX POWER HOLDINGS INC(FLUX.US) was downgraded by Lake Street to $4 (current price $0.60, implied upside 567.89%); Electra Battery Materials Corp (Electra Battery Materials Corp(ELBM.US)) was downgraded by HC Wainwright & Co. to $2 (current price $0.63, implied upside 217.66%); MDxHealth (MDxHealth S.A.(MDXH.US)) was downgraded by BTIG to $2 (current price $0.74, implied upside 169.14%); Envoy Medical (Envoy Medical, Inc. Class A(COCH.US)) was downgraded by HC Wainwright & Co. to $2 (current price $0.75, implied upside 166.67%). This "artificial upside" emerges when a stock crashes but analysts hold firm on their price targets — a "Market Capitulation vs. Analyst Price Floors" signal, not a consensus bullish view.

Signal 2: $BABA — Bulls and Bears Clash, Alibaba divided

Alibaba Group Holding Ltd. Sponsored ADR(BABA.US) saw upgrades from J.P. Morgan, Barclays, and others today, alongside downgrades from Baird, with some institutions assigning "Equal-weight." Simultaneous upgrades and downgrades act as a signal in themselves: Alibaba's long-term consensus is currently detached from its short-term price action.

Signal 3: Initiation Clusters = Fresh Bullish Bets

Today, 25 stocks received initial coverage from brokerages (Accel Entertainment, Inc. Class A(ACEL.US), Analog Devices, Inc.(ADI.US), Advanced Micro Devices, Inc.(AMD.US), Broadcom Limited(AVGO.US), California BanCorp(BCAL.US), Everus Construction Group, Inc.(ECG.US), Eldorado Gold Corporation(EGO.US), etc.). This signifies a "wave of new coverage"—Wall Street is placing fresh bullish bets on these names, serving as high-volatility catalysts during the price discovery phase.

Catalyst Calendar

The following catalyst events are sourced from company IR announcements, public earnings calendars, and clinical registries (e.g., ClinicalTrials.gov / company disclosures). They reflect known time windows and are subject to official company announcements. This is not investment advice.

⚠️ Compliance & Disclaimer

This content is compiled by our editorial team based on publicly available institutional research and market data. It does not constitute any investment advice or solicitation to buy or sell securities.

The "Upside" is calculated as (Target Price / Current Price - 1) on a 12-month target basis, which does not equal actual expected returns. Target prices carry risks of lag and deviation.

Liquidity and volatility metrics (such as Volume Ratio, ATR, 52-Week Range) are objective data derived from US market closing prices and are provided strictly for technical reference, not as trading advice.

All rating actions are compiled from public rating information as of Aug 24, and do not represent future rating changes.

Some of the covered stocks are small-caps, which generally exhibit lower liquidity, significant daily volatility, and may still be in loss-making or clinical stages. Their prices are highly sensitive to news flow, and investment risks are significantly higher than for large-cap blue chips. Please exercise extra caution.

Investment involves risks. Decisions should be aligned with your personal risk tolerance, and you should consult a licensed advisor.